Global experiments in rare disease innovation

As described in the accompanying perspective, emerging models for orphan drug innovation take different approaches to evidence generation, approval pathways, and care delivery.

BioCentury identified six models — in six countries — that are each re-routing the traditional path to patient access to medicines for very rare diseases. ...